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I have recently been invited to become an editor of a new open-access journal, ADMET & DMPK. I am 
honored to take up this exciting and challenging position. At first glance, the journal name is just a 
combination of two acronyms/disciplines in the pharmaceutical industry: ADMET (absorption, distribution, 
metabolism, excretion and toxicology) and DMPK (drug metabolism and pharmacokinetics), which sounds 
odd. Practically speaking, ADMET refers to a suite of in vitro assays that address various aspects of the 
pharmacokinetic performance of a drug, while DMPK more often refers to a drug’s in vivo pharmacokinetic 
performance. On thinking about it in more depth, it makes perfect sense to consider these two disciplines 
together, as a good DMPK profile of a drug candidate would be difficult to achieve without optimal ADMET 
properties, and both play an indispensable role in pre-clinical drug discovery. Here, I will share my views on 
the synergistic roles of these two disciplines, and how our new journal might help to foster the 
development of ADMET and DMPK. 
The discovery and development of a new candidate drug is a resource intensive and challenging process 
in the pharmaceutical industry. It involves evaluating the parameters affecting the likely success of a drug 
candidate in the preclinical, clinical and commercial phases of drug development. To maximize the chance 
of success in the clinic, it is crucial to generate and optimize quality lead compounds in the discovery 
phase. Ideally, the discovery project should include: (1) a sound clinical hypothesis, (2) the right drug target 
and (3) the right chemical agents/series, with demonstrated exposure through the preferred route of 
administration in a pre-clinical species. To effectively guide drug discovery efforts during lead optimization, 
it is essential to develop a pharmacodynamic model, which provides a means with which to evaluate 
whether the exposure level of the tested compound is sufficient to elicit a desirable pharmacological 
response.  Clearly, pharmacokinetic studies provide a measure of the exposure level of the tested 
compound, which directly addresses item (3).  
The prevalence of high throughput and combinational methods in drug discovery has led to an increase 
in the number of new chemical entities to be evaluated in the early discovery phase. Standard 
pharmacokinetic studies are no longer able to cope with the number of tests required. To mitigate the risk 
of failure due to poor pharmacokinetics, the pharmaceutical industry has developed medium/high 
throughput in vitro ADMET studies to evaluate potential lead compounds before carrying out 
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pharmacokinetic studies in pre-clinical species. Table 1 lists representative examples of some in vitro 
ADMET assays. 
Table 1.  Some common in vitro ADMET assays 
Assay Issue(s) to be addressed 
Caco-2 permeability Oral absorption 
Transporter study Oral absorption, drug–drug interactions 
Protein/serum binding Distribution 
Hepatocyte stability Metabolism 
Gut stability Metabolism 
CYP450 inhibition Drug–drug interactions 
Metabolite identification Metabolic mechanism 
hERG /cardiac ion channels QT liability, cardiotoxicity 
  
Physicochemical properties such as aqueous solubility, dissolution, lipophilicity and chemical stability 
are often regarded as the key parameters governing the ADMET properties. For instance, a poorly soluble 
research compound may suffer from incomplete oral absorption, which could lead to low systematic 
exposure, and highly lipophilic compounds are likely to show high metabolic clearance.  With the advance 
in numerical/statistical techniques, it is now possible to use the knowledge base from existing research 
compounds/drugs to build predictive models for in silico assessment of ADMET and physicochemical 
properties. The in silico approach is very useful in the drug design process and for prioritizing the synthetic 
and/or testing resources for those compounds that are most likely to show good pharmacokinetic profiles. 
It is not uncommon to encounter situations in which the potential lead compound shows good 
physiochemical properties and reasonable ADMET properties, but exhibits poor systematic exposure in a 
pharmacokinetic study. Bespoke ADMET studies could then be used as problem solving tools to identify 
such issues. Typical examples could be the differentiation between gut and hepatic metabolism, and the 
effects of uptake transporters and/or efflux transporters in absorption or clearance. In such cases, ADMET 
and DMPK studies should be conducted together as necessary with the aim of identifying the root cause 
and guiding the design of new compounds/approaches to address the problem. As the chemical series 
progresses, all available data from pharmacokinetic studies and in vitro ADMET studies could be used for 
scaling purpose. Generally, a simple allometric approach may be used to extrapolate the animal data to 
human data and thus predict pharmacokinetic parameters and, together with 
pharmacokinetic/pharmacodynamic data, the therapeutic dose levels in humans. 
I hope this journal will provide a platform for all scientists working in ADMET and DMPK areas to 
publish their results/research findings in a timely manner. The journal welcomes original scientific 
contributions from all areas of absorption, distribution, metabolism, excretion, toxicology and 
pharmacokinetics of drugs. I firmly believe in the importance of exchange of knowledge and shared 
learning, which will help drug discovery scientists to come up with better quality lead compounds, and 
hopefully to minimize costly clinical failures. 
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